One cross-sectional study compared patients with early- and late-onset AD, and found that glial fibrillary acidic protein (GFAP) was elevated in both groups of AD patients compared to controls, suggesting its use as a marker in AD and confirming astrocyte activation and degeneration as a part of the pathology of the disease [36]. The gene discussed is GFAP; the disease is Alzheimer disease.